Form 4: Viracta Therapeutics CEO Acquires 475,000 Stock Options
SEC Form 4 Filing
Viracta Therapeutics CEO, Mark Rothera, reports the acquisition of 475,000 stock options on March 12, 2024.
Summary
- Mark Rothera, the President and CEO of Viracta Therapeutics, acquired 475,000 stock options on March 12, 2024.
- The exercise price of these options is $0.985.
- The options vest monthly, with 1/48th of the total shares vesting each month starting from January 1, 2024, contingent upon continued service.
- The options expire on March 12, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies as part of executive compensation packages. It provides transparency into the holdings of company insiders.
Key Dates
| Date | Description |
|---|---|
| January 1, 2024 | Vesting Commencement Date for the stock options. |
| March 12, 2024 | Date of the transaction where the CEO acquired the stock options. |
| March 12, 2034 | Expiration date of the stock options. |
| March 13, 2024 | Date of the Form 4 filing. |
Keywords
stock options, Form 4, Viracta Therapeutics, Mark Rothera, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.